WAT Share Price | Waters Corp. Stock Analysis & Recommendation

Q: How big is Waters Corp.?

Market Cap: As of Jun 18, Waters Corp. has a market capitalization of 54,718.27 million, categorizing it as a Large Cap company.Recent Quarterly Performance: For the latest four quarters, Waters Corp. reported net sales of 2,983.25 million and a net profit of 657.02 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,828.51 million and total assets of 4,553.80 million.

Q: What does Waters Corp. do?

Overview:Waters Corporation is an analytical instrument manufacturer operating in the Pharmaceuticals & Biotechnology industry, with a market capitalization in the large-cap bracket.Financial Snapshot:- Net Sales: 662 Million (Quarterly Results - Mar 2025)- Net Profit: 121 Million (Quarterly Results - Mar 2025)- Market cap: USD 54,718.27 Million (Large Cap)Key Metrics:- P/E: 85.00- Dividend Yield: 0.00%- Debt Equity: 0.56- Return on Equity: 33.82%- Price to Book: 27.88Contact Details:- Address: 34 MAPLE ST, MILFORD MA: 01757-3604- Tel: ['1 508 4782000', '1 508 4823448']- Fax: 1 508 8721990- Website: https://www.waters.com/nextgen/us/en.html

Q: Is Waters Corp. technically bullish or bearish?

As of 3 October 2025, the technical trend for Waters Corp. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend and the KST showing bearish signals on both weekly and monthly time frames. While the weekly MACD and Dow Theory suggest a mildly bullish outlook, the overall sentiment remains cautious due to the monthly indicators leaning bearish. In terms of performance, Waters Corp. has outperformed the S&P 500 in the past week and month, but it has significantly underperformed over the year and since the beginning of the year, with returns of -7.06% and -11.69% compared to the S&P 500's 17.82% and 14.18%, respectively.

Q: Is Waters Corp. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Waters Corp. has moved from expensive to attractive, indicating a shift in perception regarding its value. The company appears to be undervalued, particularly in comparison to its peers. Key valuation ratios include a P/E ratio of 85, an EV to EBITDA of 54.96, and a PEG ratio of 11.06, which suggest that despite its high valuations, there may be growth potential that is not fully reflected in the current price.In the peer comparison, Waters Corp. has a P/E ratio significantly higher than ResMed, Inc. at 37.73 and Agilent Technologies, Inc. at 27.42, which are both in the same industry. Additionally, the EV to EBITDA ratio of 54.96 is higher than that of ResMed, which stands at 27.08, further emphasizing the relative valuation landscape. Over the past three years, Waters Corp. has returned 19.67%, while the S&P 500 has significantly outperformed with a return of 81.19%, highlighting a potential opportunity for investors as the stock may be undervalued relative to its growth prospects.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.5 M

Shareholding (Dec 2025)

FII

41.78%

Held by 385 FIIs

DII

20.18%

Held by 47 DIIs

Promoter

0.05%

How big is Waters Corp.?

22-Jun-2025

As of Jun 18, Waters Corp. has a market capitalization of $54.72 billion, with net sales of $2.98 billion and a net profit of $657 million over the latest four quarters.

View full answer

What does Waters Corp. do?

22-Jun-2025

Waters Corporation is a large-cap manufacturer of analytical instruments primarily for the Pharmaceuticals & Biotechnology industry, with quarterly net sales of $662 million and a net profit of $121 million as of March 2025. Key metrics include a P/E ratio of 85.00 and a return on equity of 33.82%.

View full answer

Who are in the management team of Waters Corp.?

22-Jun-2025

As of March 2022, the management team of Waters Corp. includes Chairman Christopher O'Connell, CEO Dr. Udit Batra, and several independent directors: Thomas Salice, Linda Baddour, Michael Berendt, Edward Conard, and Gary Hendrickson. They oversee the company's strategic direction and operations.

View full answer

Is Waters Corp. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Waters Corp. is in a mildly bearish trend, with daily moving averages and KST indicating bearish signals, despite recent outperformance against the S&P 500 over the past week and month, while significantly underperforming year-to-date.

View full answer

Is Waters Corp. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Waters Corp. is considered undervalued compared to its peers, with a high P/E ratio of 85 and an EV to EBITDA of 54.96, suggesting potential growth that may not be fully reflected in its price, despite its lower return of 19.67% over the past three years compared to the S&P 500's 81.19%.

View full answer

Compare Waters Corp. with Similar Stocks

Hologic, Inc.Baxter International, Inc.STERIS Plc (Ireland)

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

High Management Efficiency with a high ROCE of 47.77%

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.17 times

Poor long term growth as Net Sales has grown by an annual rate of 5.98% and Operating profit at 4.74% over the last 5 years

With ROCE of 27.82%, it has a fair valuation with a 18.75 Enterprise value to Capital Employed

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 58,501 Million (Mid Cap)

P/E

87.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.32

Return on Equity

26.32%

Price to Book

22.84

Revenue and Profits:

Net Sales:

932 Million

(Quarterly Results - Dec 2025)

Net Profit:

225 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-21.25%

6 Months

-2.2%

1 Year

-21.62%

2 Years

-15.84%

3 Years

-0.66%

4 Years

-10.22%

5 Years

10.76%

Waters Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

6.00%

EBIT Growth (5y)

3.99%

EBIT to Interest (avg)

14.34

Debt to EBITDA (avg)

1.17

Net Debt to Equity (avg)

0.56

Sales to Capital Employed (avg)

0.84

Tax Ratio

16.08%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

47.77%

ROE (avg)

133.16%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

22.84

EV to EBIT

70.23

EV to EBITDA

56.45

EV to Capital Employed

17.55

EV to Sales

18.74

PEG Ratio

29.56

Dividend Yield

ROCE (Latest)

24.98%

ROE (Latest)

26.32%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 128 Schemes (37.98%)

Foreign Institutions

Held by 385 Foreign Institutions (41.78%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 6.84% vs 6.49% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -2.68% vs 7.03% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "932.40",
          "val2": "872.70",
          "chgp": "6.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "363.00",
          "val2": "342.20",
          "chgp": "6.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "14.30",
          "val2": "19.00",
          "chgp": "-24.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-39.20",
          "val2": "-1.30",
          "chgp": "-2,915.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "225.20",
          "val2": "231.40",
          "chgp": "-2.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "333.00%",
          "val2": "336.40%",
          "chgp": "-0.34%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 6.99% vs 0.07% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.75% vs -0.69% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3,165.30",
          "val2": "2,958.40",
          "chgp": "6.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,101.40",
          "val2": "1,043.70",
          "chgp": "5.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "69.50",
          "val2": "89.70",
          "chgp": "-22.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-81.80",
          "val2": "-26.30",
          "chgp": "-211.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "642.60",
          "val2": "637.80",
          "chgp": "0.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "282.80%",
          "val2": "287.90%",
          "chgp": "-0.51%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

932.40

872.70

6.84%

Operating Profit (PBDIT) excl Other Income

363.00

342.20

6.08%

Interest

14.30

19.00

-24.74%

Exceptional Items

-39.20

-1.30

-2,915.38%

Consolidate Net Profit

225.20

231.40

-2.68%

Operating Profit Margin (Excl OI)

333.00%

336.40%

-0.34%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 6.84% vs 6.49% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -2.68% vs 7.03% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

3,165.30

2,958.40

6.99%

Operating Profit (PBDIT) excl Other Income

1,101.40

1,043.70

5.53%

Interest

69.50

89.70

-22.52%

Exceptional Items

-81.80

-26.30

-211.03%

Consolidate Net Profit

642.60

637.80

0.75%

Operating Profit Margin (Excl OI)

282.80%

287.90%

-0.51%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 6.99% vs 0.07% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 0.75% vs -0.69% in Dec 2024

All Annual Results

Company CV

About Waters Corp.

Waters Corp.

Pharmaceuticals & Biotechnology

Waters Corporation is an analytical instrument manufacturer. The Company operates through two segments: Waters and TA. It designs, manufactures, sells and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans. It also designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments through its TA product line. It is also a developer and supplier of software-based products that interface with the Company's instruments, as well as other suppliers' instruments. Its LC and LC-MS instruments are utilized in a range of industries to detect, identify, monitor and measure the chemical, physical and biological composition of materials, and to purify a range of compounds.

Company Coordinates

Company Details

34 MAPLE ST , MILFORD MA : 01757-3604

Tel: 1 508 47820001 508 4823448

https://www.waters.com/nextgen/us/en.html

Registrar Details